Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PIQLF's PB Ratio is ranked worse than 63.03% of 1228
companies
in the Biotechnology industry
Industry Median: 2.885
vs PIQLF: 4.33
During the past 12 months, Proteomics International Laboratories's average Book Value Per Share Growth Rate was 7.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 36.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 10.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.90% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Proteomics International Laboratories was 36.30% per year. The lowest was -4.70% per year. And the median was 15.05% per year.
Back to Basics: PB Ratio
Proteomics International Laboratories (OTCPK:PIQLF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Proteomics International Laboratories PB Ratio Related Terms
Proteomics International Laboratories PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteomics International Laboratories PB Ratio Chart
For the Biotechnology subindustry, Proteomics International Laboratories's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteomics International Laboratories PB Ratio vs Biotechnology Industry
Proteomics International Laboratories PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Proteomics International Laboratories (PIQLF) has a PB Ratio of 8.67 as of Jul. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Proteomics International Laboratories and its competitors. This is 20% below median its historical median of 10.83. Over the past decade, Proteomics International Laboratories' PB Ratio has ranged from 1.33 to 35.94. According to the industry distribution chart, Proteomics International Laboratories ranks #774 out of 1228 companies in the Biotechnology industry, placing it in the top 63%.
Is Proteomics International Laboratories' PB Ratio too high?
Proteomics International Laboratories' current PB Ratio of 8.67 is 20% below median its 10-year median of 10.83. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 35.94. The Biotechnology industry median PB Ratio is 2.89. Proteomics International Laboratories' value of 8.67 is 200.5% above this industry median. Based on the distribution chart, Proteomics International Laboratories ranks #774 out of 1228 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Proteomics International Laboratories has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Proteomics International Laboratories' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Proteomics International Laboratories ranks #774 out of 1228 companies for PB Ratio. This places Proteomics International Laboratories in the lower half of its industry. The industry median PB Ratio is 2.89. Proteomics International Laboratories' value of 8.67 is 200.5% above this benchmark. Historically, Proteomics International Laboratories' own PB Ratio has ranged from 1.33 to 35.94 over the past decade. While the company's 10-year median is 10.83 vs. the industry median of 2.89, Proteomics International Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.89, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteomics International Laboratories's current PB Ratio of 8.67 is 200.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Proteomics International Laboratories and its competitors. For the Biotechnology industry, the median PB Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteomics International Laboratories's current PB Ratio is 8.67, which is 20% below median its own 10-year median of 10.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteomics International Laboratories stock overvalued right now?
Proteomics International Laboratories (PIQLF) has a current PB Ratio of 8.67. The stock's GF Value™ is $0.64, compared to a current price of $0.26 — trading 59.4% below its estimated fair value. The current PB Ratio is 8.67, which is 20% below median its 10-year median of 10.83 and 200.5% above the Biotechnology industry median of 2.89. Proteomics International Laboratories' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Proteomics International Laboratories (PIQLF), the current PB Ratio is 8.67 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Proteomics International Laboratories (PIQLF) Overvalued in 2026?
Based on GuruFocus' analysis, Proteomics International Laboratories stock appears to be undervalued.
The current stock price of $0.26 is trading 59.4% below its estimated GF Value™ of $0.64.
Key valuation signals for PIQLF:
PB Ratio: 8.67 (20% below median its 10-year median of 10.83)
GF Value™: $0.64 vs. price of $0.26 (59.4% below fair value)
Industry Position: 200.5% above the Biotechnology median (#774 of 1228)
No single metric tells the full story. See the PIQLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Proteomics International Laboratories Business Description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. It is a pioneering medical technology company operating at the forefront of predictive diagnostics and precision medicine. The Company specialises in proteomics-the industrial-scale study of the structure and function of proteins. Its pipeline includes Promarker, Pipeline PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
31GF Score
Get the complete analysis for PIQLF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PIQLF has been successfully added to your 
